Literature DB >> 7127402

Growth characteristics of human melanoma xenografts.

E K Rofstad, O Fodstad, T Lindmo.   

Abstract

The growth of twelve human malignant melanomas in athymic nude mice was studied. Gompertz curves were fitted to volumetric growth data. DNA histograms were obtained with flow cytometry. Each of the twelve melanomas exhibited a characteristic growth pattern, indicating that inherent properties of the tumours are important for the growth control. The theoretical maximum volumes (Vmax) ranged from 208 to 12,900 mm3, the volume doubling times (Td) from 2.8 to 15.3 days (V = 50 mm3) and from 3.8 to 64.6 days (V = 200 mm3), and the fraction of cells in S from 5 to 21%. Tumours with short Td were characterized by a higher growth fraction and probably by a lower cell loss factor than those with long Td. The growth was also influenced by the nude mouse host, as indicated by the values for Vmax, which were similar to those reported for mouse tumours (geometric mean = 8100 mm3), but considerably lower than the volumes of many tumours in man. Also the Td-values for the xenografts were generally lower than those reported for tumours in man, presumably due to a lower cell loss factor. During serial transplantation the growth rate of one of the melanomas increased abruptly, probably because of both an increased growth fraction and a reduced cell loss factor. The latter result demonstrates the necessity of keeping basic biological parameters of xenografts under observation during serial transplantation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7127402     DOI: 10.1111/j.1365-2184.1982.tb01576.x

Source DB:  PubMed          Journal:  Cell Tissue Kinet        ISSN: 0008-8730


  11 in total

Review 1.  Human tumor xenografts as model for drug testing.

Authors:  J Mattern; M Bak; E W Hahn; M Volm
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

2.  Growth kinetics of four human breast carcinomas grown in nude mice.

Authors:  M Spang-Thomsen; K Rygaard; L Hansen; A C Halvorsen; L L Vindeløv; N Brünner
Journal:  Breast Cancer Res Treat       Date:  1989-11       Impact factor: 4.872

3.  Micronucleus formation in human melanoma xenografts following exposure to hyperthermia.

Authors:  E K Rofstad; K H Falkvoll; P Oftedal
Journal:  Radiat Environ Biophys       Date:  1984       Impact factor: 1.925

4.  Growth of human bronchial carcinomas in nude mice.

Authors:  J Mattern; S Jäger; J Sonka; K Wayss; M Volm
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

5.  Radiation and heat sensitivity of cells from two slowly growing human melanoma xenografts.

Authors:  E K Rofstad; A Wahl; T Brustad
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

6.  The initial engraftment of tumor cells is critical for the future growth pattern: a mathematical study based on simulations and animal experiments.

Authors:  Bertin Hoffmann; Tobias Lange; Vera Labitzky; Kristoffer Riecken; Andreas Wree; Udo Schumacher; Gero Wedemann
Journal:  BMC Cancer       Date:  2020-06-05       Impact factor: 4.430

7.  Progressive growth of a human pleural mesothelioma xenografted to athymic rats and mice.

Authors:  C J Lindén; L Johansson
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

8.  Tumour growth delay following single dose irradiation of human melanoma xenografts. Correlations with tumour growth parameters, vascular structure and cellular radiosensitivity.

Authors:  E K Rofstad; T Brustad
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

9.  Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer.

Authors:  M L Friedlander; P Russell; I W Taylor; M H Tattersall
Journal:  Br J Cancer       Date:  1985-03       Impact factor: 7.640

10.  Disaggregation of human solid tumours by combined mechanical and enzymatic methods.

Authors:  S A Engelholm; M Spang-Thomsen; N Brünner; I Nøhr; L L Vindeløv
Journal:  Br J Cancer       Date:  1985-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.